Inhibition of Dendritic Cell Generation and Function by Serum from Prostate Cancer Patients: Correlation with Serum-Free PSA
Tumor produces a number of immunosuppressive factors that block maturation of dendritic cells (DCs). Here, we demonstrated that endogenous factors presented in the serum of patients with prostate cancer (CaP) inhibited the generation of functionally active DCs from CD14+ monocytes in vitro. We have shown a significant inhibitory potential of serum obtained from patients with CaP and benign prostate hyperplasia benign prostatic hyperplasia (BPH) when compared with serum from healthy volunteers. As assessed by flow cytometry, expression of CD83, CD86, and CD40 molecules was strongly inhibited by CaP and BPH serum. In addition, these DCs were weak stimulators of allogeneic T cell proliferation when compared with DCs produced in the presence of healthy volunteer serum. Statistical analysis of the results revealed a positive relationship between the inhibition of expression of DC markers CD83 and CD80 and the levels of serum-free prostate-specific antigen (PSA). These data suggest that the DC system may be impaired in CaP patients.
KeywordsProstate Cancer Prostate Specific Antigen Benign Prostatic Hyperplasia Benign Prostatic Hyperplasia Patient Dendritic Cell Function
Unable to display preview. Download preview PDF.
- Arya, M., Bott, S.R., Shergill, I.S., Ahmed, H.U., Williamson, M. and Patel, H.R. (2006) The metastatic cascade in prostate cancer. Surg. Oncol. 23, 77–83.Google Scholar
- Catalona, W.J., Partin, A.W., Slawin, K.M., Brawer, M.K., Flanigan, R.C., Patel, A., Richie, J.P., deKernion, J.B., Walsh, P.C., Scardino, P.T., Lange, P.H., Subong, E.N., Parson, R.E., Gasior, G.H., Loveland, K.G. and Southwick, P.C. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542–1547.CrossRefPubMedGoogle Scholar
- Comuzzi, B. and Sadar, M.D. (2006) Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cell Sci. 3, 61–81.Google Scholar
- Healy, C.G., Simons, J.W., Carducci, M.A., DeWeese, T.L., Bartkowski, M., Tong, K.P. and Bolton, W.E. (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32, 109–119.CrossRefPubMedGoogle Scholar
- Ivshina, A.V., Zhumagazin Zh, D., Zabotina, T.N., Matveev, B.P. and Kadagidze, Z.G. (1995) Effect of the spread of the process and treatment on the phenotype of peripheral blood lymphocytes in patients with prostatic cancer. Urologiia. i. Nefrologiia 9, 36–38.Google Scholar
- Li, N., Qin, H., Li, X., Zhou, C., Wang, D., Ma, W., Lin, C., Zhang, Y., Wang, S. and Zhang, S. (2006) Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J. Clin. Immunol. 27, 117–130.CrossRefPubMedGoogle Scholar
- Salgaller, M.L., Lodge, P.A., McLean, J.G., Tjoa, B.A., Loftus, D.J., Ragde, H., Kenny, G.M., Rogers, M., Boynton, A.L. and Murphy, G.P. (1998) Report of immune monitoring of prostate cancer patients undergoing T cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen. Prostate 35, 144–151.CrossRefPubMedGoogle Scholar
- Shamdas, G.J., Ahmann, F.R., Matzner, M.B. and Ritchie, J.M. (1993) Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 71, 3594–3600.Google Scholar
- Simons, J.W., Mikhak, B., Chang, J.F., DeMarzo, A.M., Carducci, M.A., Lim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F. and Nelson, W.G. (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160–5168.PubMedGoogle Scholar
- Speiser, D.E., Miranda, R., Zakarian, A., Bachmann, M.F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R.M. and Ohashi, P.S. (1997) Self antigens expressed by soild tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186, 645–653.CrossRefPubMedGoogle Scholar
- Troy, A., Davidson, P., Atkinson, C. and Hart, D. (1999) Renal cell carcinoma and prostate cancer inhibit dendritic cell activation. Aust. N. Z. J. Surg. 69, A111–A112.Google Scholar